Clinical Trial

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

Recruiting
View on ClinicalTrials.gov →
Summary
To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel. The information collected will be used to determine if there are any "biomarkers" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-02 -> 2026-12-02 2026-07-24
minor Completion pushed: 2026-07-02 -> 2026-12-02 2026-07-24
Trial Details
NCT Number NCT06320717
Lead Sponsor Roswell Park Cancer Institute
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 100 participants
Start Date 2024-01-02
Primary Completion 2026-12-02 (estimated)
Study Completion 2026-12-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-23